Complete financial analysis of Insmed Incorporated (INSM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Insmed Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Trans Global Group, Inc. (TGGI) Income Statement Analysis – Financial Results
- Raisio plc (RAIVV.HE) Income Statement Analysis – Financial Results
- Ashford Hospitality Trust, Inc. (AHT-PF) Income Statement Analysis – Financial Results
- Carnival Industrial Corporation (1417.TW) Income Statement Analysis – Financial Results
- International CSRC Investment Holdings Co., Ltd. (2104.TW) Income Statement Analysis – Financial Results
Insmed Incorporated (INSM)
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 305.21M | 245.36M | 188.46M | 164.41M | 136.47M | 9.84M | 0.00 | 0.00 | 0.00 | 11.50M | 11.50M | 0.00 | 4.42M | 6.92M | 10.37M | 11.70M | 7.53M | 991.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 663.16K |
| Cost of Revenue | 65.57M | 55.13M | 44.15M | 39.87M | 24.21M | 2.42M | 2.90M | 2.44M | 1.98M | 33.53M | 29.64M | 21.37M | 0.00 | 0.00 | 0.00 | 0.00 | 576.00K | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -86.57K |
| Gross Profit | 239.64M | 190.23M | 144.31M | 124.54M | 112.26M | 7.41M | -2.90M | -2.44M | -1.98M | -22.03M | -18.14M | -21.37M | 4.42M | 6.92M | 10.37M | 11.70M | 6.95M | -499.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 749.74K |
| Gross Profit Ratio | 78.52% | 77.53% | 76.57% | 75.75% | 82.26% | 75.36% | 0.00% | 0.00% | 0.00% | -191.61% | -157.77% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 92.35% | -50.35% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 113.05% |
| Research & Development | 571.01M | 397.52M | 272.74M | 181.16M | 131.71M | 145.28M | 109.75M | 122.72M | 74.28M | 56.29M | 44.28M | 29.78M | 27.92M | 4.76M | 9.21M | 21.05M | 18.94M | 21.09M | 21.84M | 23.32M | 7.14M | 18.08M | 35.51M | 21.61M | 6.35M |
| General & Administrative | 344.50M | 244.98M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 0.00 | 0.00 | 0.00 | 0.00 | 5.73M | 2.98M | 3.48M | 2.98M | 4.98M | 9.55M | 0.00 |
| Selling & Marketing | 0.00 | 20.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 344.50M | 265.78M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 25.68M | 5.73M | 4.24M | 3.48M | 2.98M | 4.98M | 9.55M | 2.44M |
| Other Expenses | 33.75M | 5.05M | 5.05M | 5.00M | 4.99M | 602.00K | 300.00K | 119.00K | -33.00K | 141.00K | -33.00K | 0.00 | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 32.79M | 5.73M | 4.24M | 3.60M | 18.37M | 95.00K | 0.00 | 2.53M |
| Operating Expenses | 949.26M | 668.36M | 512.07M | 389.77M | 347.50M | 314.75M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.39M | 53.87M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.88M |
| Cost & Expenses | 1.01B | 723.48M | 556.22M | 429.65M | 371.71M | 317.17M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.97M | 55.36M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.79M |
| Interest Income | 0.00 | 11.08M | 174.00K | 1.70M | 9.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.85M | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 607.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.69M | 26.45M | 40.47M | 29.56M | 27.71M | 25.47M | 5.93M | 3.50M | 2.89M | 2.42M | 2.41M | 763.00K | 10.00K | 109.00K | 781.00K | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.58M | 24.27M | 27.85M | 20.08M | 10.18M | 4.83M | 2.90M | 2.44M | 1.98M | 1.07M | 680.00K | 561.00K | 343.00K | 54.00K | 707.00K | 1.04M | 406.00K | 3.37M | 12.90M | 34.00K | 96.00K | 346.00K | 1.54M | 789.00K | 86.57K |
| EBITDA | -660.18M | -429.44M | -375.09M | -250.37M | -215.67M | -293.78M | -184.10M | -170.24M | -115.28M | -86.09M | -54.20M | -40.05M | -59.31M | -6.19M | 120.32M | -13.37M | -18.87M | -49.07M | -13.79M | -27.17M | -10.49M | -34.15M | -38.64M | -30.31M | -8.04M |
| EBITDA Ratio | -216.30% | -186.75% | -198.12% | -158.03% | -169.11% | -3,106.12% | 0.00% | 0.00% | 0.00% | -758.47% | -472.77% | 0.00% | -801.13% | -116.14% | -76.81% | -109.99% | -266.08% | -4,429.97% | -11,096.95% | -19,993.43% | -6,914.00% | -830.03% | -13,055.41% | 33,536.67% | -1,212.93% |
| Operating Income | -709.63M | -478.12M | -367.76M | -265.23M | -235.25M | -307.34M | -188.92M | -173.40M | -117.49M | -87.37M | -55.02M | -42.44M | -61.72M | -8.09M | -8.67M | -14.41M | -20.44M | -54.37M | -27.43M | -27.43M | -10.59M | -37.02M | -40.19M | -81.54M | -8.13M |
| Operating Income Ratio | -232.51% | -194.87% | -195.14% | -161.32% | -172.38% | -3,124.94% | 0.00% | 0.00% | 0.00% | -759.70% | -478.39% | 0.00% | -1,397.31% | -116.92% | -83.62% | -123.18% | -271.47% | -5,486.68% | -20,941.98% | -20,018.25% | -7,057.33% | -1,893.81% | -13,576.35% | -135,891.67% | -1,225.98% |
| Total Other Income/Expenses | -37.39M | -2.03M | -61.32M | -27.46M | -18.32M | -16.74M | -4.00M | -2.78M | -2.66M | -2.22M | -2.28M | -1.14M | -23.94M | 1.74M | 127.50M | -1.26M | 477.00K | -1.77M | -13.50M | 222.00K | 288.00K | 607.00K | 3.02M | 1.87M | 0.00 |
| Income Before Tax | -747.01M | -480.15M | -436.41M | -292.69M | -253.56M | -324.08M | -192.92M | -176.18M | -120.15M | -89.58M | -57.29M | -41.37M | -59.66M | -6.36M | 118.83M | -15.67M | -19.96M | -56.14M | -40.93M | -36.42M | -10.30M | -36.42M | -37.17M | -79.66M | 0.00 |
| Income Before Tax Ratio | -244.76% | -195.69% | -231.57% | -178.02% | -185.80% | -3,295.13% | 0.00% | 0.00% | 0.00% | -778.97% | -498.21% | 0.00% | -1,350.78% | -91.84% | 1,145.54% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -26,581.75% | -6,865.33% | -1,862.76% | -12,557.09% | -132,770.00% | 0.00% |
| Income Tax Expense | 2.56M | 1.38M | -1.76M | 1.40M | 777.00K | 201.00K | -272.00K | 98.00K | -1.97M | -10.42M | -1.22M | 763.00K | 9.18M | 78.00K | 477.00K | 1.26M | 0.00 | 1.77M | 0.00 | -9.21M | -288.00K | 1.93M | -74.34M | 200.00K | -337.57K |
| Net Income | -749.57M | -481.53M | -434.65M | -294.09M | -254.34M | -324.28M | -192.65M | -176.27M | -118.18M | -79.16M | -56.07M | -41.37M | -59.66M | -6.43M | 118.35M | -15.67M | -19.96M | -56.14M | -40.93M | -27.20M | -10.30M | -36.42M | -37.17M | -79.86M | -7.79M |
| Net Income Ratio | -245.59% | -196.26% | -230.63% | -178.87% | -186.37% | -3,297.17% | 0.00% | 0.00% | 0.00% | -688.34% | -487.59% | 0.00% | -1,350.78% | -92.96% | 1,140.94% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -19,856.20% | -6,865.33% | -1,862.76% | -12,557.09% | -133,103.33% | -1,175.08% |
| EPS | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| EPS Diluted | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| Weighted Avg Shares Out | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.84M | 66.58M | 61.85M | 58.51M | 43.02M | 34.98M | 26.52M | 23.35M | 13.25M | 12.71M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
| Weighted Avg Shares Out (Dil) | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.89M | 66.58M | 61.89M | 58.63M | 43.10M | 34.98M | 26.55M | 23.35M | 13.25M | 12.73M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
BRIDGEWATER, N.J. , Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Feb. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees.
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million— —2024 Global ARIKAYCE Revenues Expected to be Between $340 Million and $360 Million, Reflecting...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Jan. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new...
Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J. , Jan. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 42nd Annual...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Dec. 5, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 14 new...
Insmed To Present at the Nasdaq 49th Investor Conference
BRIDGEWATER, N.J. , Nov. 29, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 49th...
Insmed To Present at Two November Conferences
BRIDGEWATER, N.J. , Nov. 8, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Nov. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 21 new...
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.09 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports